These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
79 related articles for article (PubMed ID: 23872178)
1. Formulation of poorly water-soluble drugs via coacervation--a pilot study using febantel. De Jaeghere W; De Geest BG; Van Bocxlaer J; Remon JP; Vervaet C; Antunes da Fonseca A Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):930-5. PubMed ID: 23872178 [TBL] [Abstract][Full Text] [Related]
2. High drug loading self-microemulsifying/micelle formulation: design by high-throughput formulation screening system and in vivo evaluation. Sakai K; Obata K; Yoshikawa M; Takano R; Shibata M; Maeda H; Mizutani A; Terada K Drug Dev Ind Pharm; 2012 Oct; 38(10):1254-61. PubMed ID: 22339057 [TBL] [Abstract][Full Text] [Related]
3. Solvent-free drug crystal engineering for drug nano- and micro suspensions. da Fonseca Antunes AB; De Geest BG; Vervaet C; Remon JP Eur J Pharm Sci; 2013 Jan; 48(1-2):121-9. PubMed ID: 23131799 [TBL] [Abstract][Full Text] [Related]
4. Soluplus® as an effective absorption enhancer of poorly soluble drugs in vitro and in vivo. Linn M; Collnot EM; Djuric D; Hempel K; Fabian E; Kolter K; Lehr CM Eur J Pharm Sci; 2012 Feb; 45(3):336-43. PubMed ID: 22172603 [TBL] [Abstract][Full Text] [Related]
5. Amino acids as co-amorphous stabilizers for poorly water soluble drugs--Part 1: preparation, stability and dissolution enhancement. Löbmann K; Grohganz H; Laitinen R; Strachan C; Rades T Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):873-81. PubMed ID: 23537574 [TBL] [Abstract][Full Text] [Related]
6. Studies on dissolution enhancement and mathematical modeling of drug release of a poorly water-soluble drug using water-soluble carriers. Ahuja N; Katare OP; Singh B Eur J Pharm Biopharm; 2007 Jan; 65(1):26-38. PubMed ID: 16962750 [TBL] [Abstract][Full Text] [Related]
7. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications. Kawabata Y; Wada K; Nakatani M; Yamada S; Onoue S Int J Pharm; 2011 Nov; 420(1):1-10. PubMed ID: 21884771 [TBL] [Abstract][Full Text] [Related]
8. Fate of febantel in the aquatic environment-the role of abiotic elimination processes. Babić S; Pavlović DM; Biošić M; Ašperger D; Škorić I; Runje M Environ Sci Pollut Res Int; 2018 Oct; 25(29):28917-28927. PubMed ID: 30105676 [TBL] [Abstract][Full Text] [Related]
9. Parallel screening approach to identify solubility-enhancing formulations for improved bioavailability of a poorly water-soluble compound using milligram quantities of material. Dai WG; Dong LC; Li S; Pollock-Dove C; Chen J; Mansky P; Eichenbaum G Int J Pharm; 2007 May; 336(1):1-11. PubMed ID: 17178444 [TBL] [Abstract][Full Text] [Related]
10. The bioavailability of febantel in dehydrated camels. Ben-Zvi Z; Gussarsky E; van Creveld C; Yagil R J Vet Pharmacol Ther; 1996 Aug; 19(4):288-94. PubMed ID: 8866457 [TBL] [Abstract][Full Text] [Related]
11. A re-assessment of the efficacy of febantel (Rintal) and fenbendazole (Panacur) against Strongyloides papillosus in sheep and goats. Grimbeek P; Terblanche HJ J S Afr Vet Assoc; 1980 Mar; 51(1):49-50. PubMed ID: 7452659 [TBL] [Abstract][Full Text] [Related]
12. Comparative pharmacokinetics of febantel and its metabolites in sheep and cattle. Delatour P; Tiberghien MP; Garnier F; Benoît E Am J Vet Res; 1985 Jun; 46(6):1399-402. PubMed ID: 4026020 [TBL] [Abstract][Full Text] [Related]
13. Fast-dissolving microparticles fail to show improved oral bioavailability. Wong SM; Kellaway IW; Murdan S J Pharm Pharmacol; 2006 Oct; 58(10):1319-26. PubMed ID: 17034654 [TBL] [Abstract][Full Text] [Related]
14. New formulation approaches to improve solubility and drug release from fixed dose combinations: case examples pioglitazone/glimepiride and ezetimibe/simvastatin. Taupitz T; Dressman JB; Klein S Eur J Pharm Biopharm; 2013 May; 84(1):208-18. PubMed ID: 23246797 [TBL] [Abstract][Full Text] [Related]
15. Development of an in vitro/in vivo correlation for lipid formulations of EMD 50733, a poorly soluble, lipophilic drug substance. Schamp K; Schreder SA; Dressman J Eur J Pharm Biopharm; 2006 Apr; 62(3):227-34. PubMed ID: 16246538 [TBL] [Abstract][Full Text] [Related]
16. Microwave-generated bionanocomposites for solubility and dissolution enhancement of poorly water-soluble drug glipizide: in-vitro and in-vivo studies. Kushare SS; Gattani SG J Pharm Pharmacol; 2013 Jan; 65(1):79-93. PubMed ID: 23215691 [TBL] [Abstract][Full Text] [Related]
17. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats. Nielsen LH; Gordon S; Holm R; Selen A; Rades T; Müllertz A Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980 [TBL] [Abstract][Full Text] [Related]
18. Influence of cryogenic grinding on properties of a self-emulsifying formulation. Chambin O; Jannin V; Champion D; Chevalier C; Rochat-Gonthier MH; Pourcelot Y Int J Pharm; 2004 Jun; 278(1):79-89. PubMed ID: 15158951 [TBL] [Abstract][Full Text] [Related]
19. Phase separation induced in gelatin-base coacervation systems by addition of water-soluble nonionic polymers II: effect of molecular weight. Jizomoto H J Pharm Sci; 1985 Apr; 74(4):469-72. PubMed ID: 3999011 [TBL] [Abstract][Full Text] [Related]
20. A nanosystem for water-insoluble drugs prepared by a new technology, nanoparticulation using a solid lipid and supercritical fluid. Park JW; Yun JM; Lee ES; Youn YS; Kim KS; Oh YT; Oh KT Arch Pharm Res; 2013 Nov; 36(11):1369-76. PubMed ID: 23780798 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]